维普中文期刊产品整合服务
85篇 您的检索式:作者名="PRATLEY R"
    题名 作者 年代 出处 被引量
1Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia显示文摘Weyer C Funahashi T Tanaka S Hotta K Matsuzawa Y Pratley R E 2001J Clin Endocrinol Metab2001,86,:1
2Familiarity of physical and metabolic characteristic that predict the development of non-insulin-dependent diabetes mellitus in Pima Indians显示文摘Sakul H Pratley R Cardon L 1997Am J Hum Genet1997,60,:1
3Relationship between muscle sympathetic nerve activity and plasma leptin con- centration显示文摘SNITKER S PRATLEY R E NIEOLSON M 1997Obes Res1997,5,4:1
4Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin added to pioglitazone in patients with type-2 diabetes: a randomized, double-blind, placebo-controlled study 显示文摘PRATLEY R E REUSCH J E FLECK P R 2009Curr Med Res Opin2009,25,10:1
5Robust improvements in fasting and prandial measures of b - cell function with vildagliptin in drug- naive patients:analysis of pooled vildagliptin monotherapy database显示文摘Pratley R E Schweizer A Rosenstock J 2008Diabetes Obes Metab2008,10,:1
6Evaluation of simple indices of insulin sensitivity and insulin secretion foruse in epidemi- ologic studies显示文摘Hanson R L Pratley R E Bogardus C 2000Am J Epidemio2000,151,2:1
7HARMONY4:52-week efficacy of albiglutide vsinsulin glargine in patients w ith type 2diabetes mellitus显示文摘Pratley R Stewart M Cirkel D 2013Diabetologia2013,,:1
8Improvements in blood pressure,glucose metabolism, and lipoprotein lipids after aerobic exercise plus weight loss in obese, hypertensive middleaged men 显示文摘Dengel D R Hagberg J M Pratley R E 1998Metabolism1998,47,9:1
9The role of impaired early insulin secretion in the pathogenesis of type 2 diabetes mellitus 显示文摘PRATLEY R E WEER C 2001Diabetologia2001,44,8:1
10Cardiovascular safety of the dipeptidyl peptidase-4 inhibitor alogliptin in type-2 diabetes mellitus 显示文摘WHITE W B PRATLEY R FLECK P 2013Diabetes Obes Metab2013,15,7:1
11Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes inadequately controlled by glyburide monotherapy显示文摘Pratley R E ipnes M S Fleck P R etal 2009Diabetes Obes Metab2009,11,2:1
12Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin added to pioglitazone in patients with type 2 diabetes: A randomized, double-blind, placebo-controlled study显示文摘Pratley R E Reusch J E B Fleck P R 2009Current Medical Research and Opinion2009,25,10:1
13Alogliptin:a new,highly selective dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes显示文摘PRATLEY R E 2009Expert Opin Pharmacother2009,10,3:1
14Evaluation of simple indices of insulin sensitivity and insulin secretion for use in epidemiological studies显示文摘Hanson R Pratley RE Bogardus C 2000Am J Epidemiol2000,151,2:1
15Resistive training increases insulin action in postmenopausal women显示文摘RYAN A S PRATLEY R E GOLDBERG A P 1996J Gerontol A-Biol1996,51,5:1
16Effects of strength training on total and regional body composition in ol- der men显示文摘TREUTH M S RYAN A S PRATLEY R E 1994J Applied Physiol1994,,2:1
17Resistance toGlyphosate in Lolium rigidum I Bioevaluation显示文摘PRATLEY J URWIN N STANTON R et ai 1999Weed Sci1999,47,:1
18One year of liraglutide treatment offers sustained and more effective glycaemic control and weight reduction compared with sitagliptin, both in combination with metformin, in patients with type 2 diabetes: a randomized, parallel-group, open-label trial显示文摘Pratley R Nauck M Bailey T 2011Int J Clin Praet2011,65,4:1
19The role of impaired early insulin secre --ation in the pathogenesis of type 2 diabetes mellitus显示文摘Pratley R E Weyer C 2001Diabe - tologia2001,44,:1
20Twelve-week monotherapy with the DPP-4 inhibitor, LAF237 improves glycemic control m patients with type 2 diabetes 显示文摘Pratley R Galbreath E 2004Diabetes2004,53,2:1
返回顶部 每页显示:
共5页 首页 上一页 第1页 下一页 末页 /5 跳转

网站首页 | 关于我们 | 联系我们 | 产品服务 | 客服中心 | 广告服务 | 版权声明 | 网站联盟 | 友情链接 | 售卡网点

版权所有© 渝B2-20050021-1 渝公网安备 50019002500403号 违法和不良信息举报中心

互联网出版许可证 新出网证(渝)字10号 全国400电话 - 免长途话费